FSHR Antibody

What criteria should researchers use when selecting an FSHR antibody for immunohistochemistry?

Antibody selection for FSHR detection requires rigorous validation against multiple specificity criteria. Based on comparative studies, researchers should prioritize antibodies with demonstrated binding to native hFSHR from different sources and confirmed lack of reactivity with non-related proteins . The methodological approach should include:

• Flow cytometry validation using known FSHR-expressing and non-expressing cell lines

• Confirmation of binding to fixed and unfixed cells

• Verification of detection at physiological expression levels

• Competition assays with FSH to confirm epitope specificity

Studies comparing commercial antibodies have shown significant variability in specificity, with FSHR323 displaying superior performance in immunohistochemical applications compared to sc-7798 and sc-13935 . For optimal results, researchers should select antibodies validated through multiple complementary approaches rather than relying on manufacturer claims alone.

How do different epitope retrieval methods affect FSHR antibody performance in paraffin-embedded tissues?

Epitope retrieval significantly impacts FSHR antibody binding efficiency in formalin-fixed paraffin-embedded (FFPE) tissues. Research indicates that different FSHR antibodies vary dramatically in their sensitivity to fixation conditions .

When working with FFPE samples, researchers should:

• Test multiple retrieval methods (heat-induced vs. enzymatic)

• Optimize buffer conditions (citrate vs. EDTA-based buffers)

• Validate antibody performance on positive control tissues with known FSHR expression

• Include parallel tests on fixation-sensitive epitopes

For antibodies like Y010913 and Y010916, fixation conditions completely mask the binding epitope, while FSHR323's epitope remains sufficiently accessible for efficient binding even after fixation . This highlights the importance of selecting antibodies specifically validated for the intended application and tissue preparation method.

How reliable are FSHR antibodies for evaluating FSHR as a potential cancer target?

The reliability of FSHR as a cancer target depends critically on antibody specificity. Research examining expression patterns in cancer tissues has produced contradictory results, largely attributable to antibody selection . For valid cancer target validation:

• Use antibodies with confirmed specificity to native, cell-presented hFSHR

• Validate antibody binding to physiological expression levels

• Confirm expression patterns with multiple detection methods

• Include appropriate positive and negative controls

Among tested antibodies, FSHR323 has demonstrated superior performance for cancer target validation. When applied to ovarian, prostatic, and renal adenocarcinomas, this antibody revealed that FSHR is predominantly expressed in peripheral tumor blood vessels rather than tumor cells themselves . This pattern challenges earlier reports and emphasizes the need for rigorous antibody validation in cancer research applications.

What methodological approaches can resolve contradictory findings regarding FSHR expression in tumor tissues?

Contradictory findings on FSHR expression in tumors can be addressed through systematic methodological approaches:

• Compare multiple antibodies with different epitope recognition patterns

• Validate expression at both protein and mRNA levels

• Use genetic reporter systems like the Fshr-ZsGreen mouse model

• Implement titration experiments to determine optimal antibody concentrations

The contradictory findings can be largely attributed to nonspecific binding of certain commercial antibodies. Studies show that antibodies like sc-7798 and sc-13935 produce staining patterns even in tissues where FSHR expression is not expected . To resolve these discrepancies:

Researchers should implement multiple complementary approaches when investigating FSHR expression in novel contexts.

What is the optimal protocol for using FSHR antibodies in Western blot applications?

For optimal Western blot detection of FSHR, researchers should follow this methodological approach:

• Sample preparation: Use whole cell extracts (30 μg protein) separated on 7.5% SDS-PAGE gels

• Transfer conditions: Optimize for high molecular weight proteins (90-120 kDa range)

• Blocking: 5% non-fat milk or BSA in TBST (1 hour at room temperature)

• Primary antibody: Dilute FSHR antibody 1:500 in blocking buffer

• Detection system: HRP-conjugated secondary antibody with chemiluminescent detection

When validating FSHR expression in different tissues or cell lines, include positive controls with known FSHR expression (e.g., granulosa cells, Sertoli cells) and negative controls. The antibody NBP2-16537 has been successfully used to detect FSHR in various whole cell extracts , but researchers should optimize conditions for their specific experimental system.

How can researchers validate FSHR antibody specificity for immunocytochemistry applications?

Validating FSHR antibody specificity for immunocytochemistry requires a multi-faceted approach:

• Cell line validation: Test on cells with endogenous FSHR expression and those with confirmed absence of expression

• Transfection controls: Use FSHR-overexpressing cells (e.g., Flp-In CHO/FSHR) as positive controls

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm binding specificity

• Signal quantification: Use consistent imaging parameters and quantitative analysis

For immunofluorescence applications, researchers should optimize:

• Fixation method (4% paraformaldehyde for 15 minutes at room temperature is standard)

• Antibody dilution (typically 1:100-1:1000 for immunocytochemistry)

• Incubation conditions (time, temperature, buffer composition)

• Counterstaining approach (e.g., Hoechst 33342 for nuclear visualization)

What evidence supports FSHR expression in non-reproductive tissues and immune cells?

Recent research has expanded our understanding of FSHR expression beyond traditional reproductive tissues. The development of reporter mouse models (Fshr-ZsGreen) has provided compelling evidence for FSHR expression in multiple immune cell populations :

• Splenic red and white pulp cells

• Bone marrow macrophages

• Various leukocyte populations including:

  • Monocytes/macrophages (CD11b+)

  • T-cells (CD3+)

  • Other immune cells including neutrophils, eosinophils, basophils, and NK cells

These findings represent a significant paradigm shift, as FSHR was traditionally thought to be restricted primarily to gonadal tissues. The methodological approach using genetic reporter systems provides strong evidence for this expanded expression pattern, with cellular localization confirmed through coexpression of lineage-specific markers (CD11b, CD3, CD4/80) .

How does FSHR antibody binding affect receptor function in experimental systems?

FSHR antibody binding can significantly impact receptor function, an important consideration for functional studies. Research has demonstrated that:

• Some antibodies (like FSHR323) can compete with FSH for receptor binding

• Pre-incubation with FSHR323 reduces FSH-induced signaling by approximately 70%

• This competition suggests binding at or near the ligand-binding domain

This functional interference has important methodological implications:

For functional studies, researchers should characterize the effect of their selected antibody on receptor activity and consider this when interpreting results.

How can researchers address background staining issues when using FSHR antibodies in IHC?

Background staining is a common challenge when using FSHR antibodies for immunohistochemistry. To minimize nonspecific signals:

• Optimize blocking conditions using:

  • Serum from the species of secondary antibody

  • Commercial blocking reagents specifically designed for IHC

  • Extended blocking times (2+ hours)

• Implement stringent washing procedures:

  • Multiple wash steps (minimum 3×5 minutes)

  • Use detergent-containing buffers (0.1-0.3% Tween-20)

  • Agitation during washing

• Validate antibody specificity:

  • Include isotype controls

  • Perform absorption controls with immunizing peptide

  • Use tissues known to be negative for FSHR expression

• Optimize antibody dilution and incubation conditions:

  • Perform titration experiments to identify optimal concentration

  • Consider overnight incubation at 4°C instead of shorter times at room temperature

Studies comparing various FSHR antibodies have demonstrated that appropriate antibody selection is crucial, as some commercial antibodies (sc-7798, sc-13935) exhibit significant background staining even in tissues without FSHR expression .

What strategies can validate FSHR antibodies for detecting physiological expression levels?

Detecting FSHR at physiological expression levels presents significant challenges that can be addressed through:

• Sensitivity validation:

  • Test antibodies on tissues with known physiological expression (e.g., Sertoli cells in testes)

  • Compare detection in overexpression systems vs. endogenous expression

  • Optimize signal amplification methods (e.g., tyramide signal amplification)

• Signal specificity confirmation:

  • Use reporter systems like Fshr-ZsGreen mice

  • Implement genetic knockdown/knockout controls when possible

  • Correlate protein detection with mRNA expression data

• Quantitative assessment:

  • Standardize image acquisition parameters

  • Implement digital image analysis for signal quantification

  • Establish signal-to-noise ratios for various tissue types

The FSHR323 antibody has demonstrated ability to detect physiological FSHR levels in Sertoli cells of human testes, while maintaining specificity . This performance at physiological concentrations is crucial for accurate analysis of expression patterns in normal tissues and pathological conditions.

How can FSHR antibodies be applied to study the role of FSHR in tumor angiogenesis?

FSHR antibodies have revealed important insights into tumor angiogenesis, with studies showing expression primarily in peripheral tumor blood vessels rather than tumor cells themselves . For researchers investigating this phenomenon:

• Methodological approach:

  • Use highly specific antibodies (FSHR323 recommended)

  • Implement double-staining with endothelial markers (CD31, CD34)

  • Analyze expression patterns at tumor margins vs. tumor core

  • Quantify vessel density in relation to FSHR expression

• Functional studies can incorporate:

  • In vitro angiogenesis assays with FSHR antibody treatment

  • Analysis of signaling pathways in isolated tumor endothelial cells

  • Correlation of FSHR expression with angiogenic factors (VEGF, bFGF)

The selective expression of FSHR in tumor vasculature suggests potential applications for targeted therapy and imaging, with antibodies like FSHR323 serving as valuable tools for both research and potential clinical applications.

What methodological considerations are important when using FSHR antibodies to study receptor internalization and trafficking?

Studying FSHR internalization and trafficking requires specialized methodological approaches:

• Live-cell imaging:

  • Use non-competing antibodies that recognize extracellular domains

  • Implement temperature-controlled conditions (4°C for binding, 37°C for internalization)

  • Consider fluorescently labeled antibody fragments (Fab) to minimize crosslinking

• Quantitative internalization assays:

  • Acid wash protocols to distinguish surface-bound vs. internalized antibody

  • Flow cytometry-based approaches for population-level quantification

  • Fixed timepoint analyses with immunofluorescence

• Antibody selection considerations:

  • Antibodies that compete with FSH (like FSHR323) may alter natural trafficking patterns

  • Non-competing antibodies are preferred for studying ligand-induced internalization

  • Consider epitope accessibility throughout the internalization process

• Controls and validation:

  • Compare antibody-based tracking with fluorescently tagged receptor constructs

  • Validate findings with pharmacological inhibitors of endocytic pathways

  • Implement parallel biochemical fractionation approaches